首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury
【24h】

Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury

机译:下一代高敏感性心肌肌钙蛋白I测定法在心肌损伤早期检测中的分析和临床应用

获取原文
           

摘要

Background: Improvements in cardiac troponin (cTn) assays have increased the rapidity with which clinicians can identify patients with changing cTn concentrations (rise or fall) indicative of acute myocardial injury. The aim of the present study was to characterize a new, high-sensitivity cTnI (hs-cTnI) assay and examine whether increased sensitivity can result in still earlier detection of evolving injury.Methods: We determined the limit of detection, precision profiles, and preliminary estimates of the 99th percentile for the Beckman Coulter hs-cTnI assay in 125 healthy individuals (age 55 years, 54% male). We compared AccuTnI? and hs-cTnI to assess whether change criteria for early concentration changes (i.e., ≥3SD for low concentrations and 20% difference for concentrations 0.10 μg/L) were exceeded in the first 2 specimens (median time between specimens, 1 h; 25th–75th percentile, 1–3 h) from subjects with symptoms suggestive of cardiac ischemia (n = 290).Results: The limit of detection for the hs-cTnI assay was 2.06 ng/L, and the 20% CV and 10% CV concentrations were 2.95 and 8.66 ng/L, respectively. The preliminary 99th percentile estimates in lithium heparin, serum, and EDTA plasma were 9.20, 8.00, and 8.60 ng/L, respectively. In 108 patients with myocardial injury based on the peak AccuTnI concentration, applying the change criteria on the 2 earliest specimens identified 81% (95% CI 73%–88%) of patients using the hs-cTnI assay compared to 62% (53%–71%) using the AccuTnI assay ( P 0.001).Conclusions: Although more extensive validation studies are required, this Beckman Coulter hs-cTnI assay appears to detect patients with evolving myocardial injury earlier.
机译:背景:心肌肌钙蛋白(cTn)检测方法的改进提高了临床医生识别具有急性心肌损伤指示的cTn浓度变化(上升或下降)的患者的速度。本研究的目的是表征一种新的高灵敏度cTnI(hs-cTnI)检测方法,并检查灵敏度的提高是否可以导致更早发现发展中的损伤。方法:我们确定了检测限,精密度和Beckman Coulter hs-cTnI分析在125位健康个体(年龄<55岁,男性占54%)中的99%的初步估计。我们比较了AccuTnI?和hs-cTnI评估前两个样品(样品之间的中位时间为1小时;第25个样品)是否超过了早期浓度变化的变化标准(即对于低浓度≥3SD,对于浓度> 0.10μg/ L≥20%的差异)症状提示心脏局部缺血(n = 290)的患者–75%,1-3小时)。结果:hs-cTnI检测的检出限为2.06 ng / L,CV和CV分别为20%和10%浓度分别为2.95和8.66 ng / L。肝素锂,血清和EDTA血浆中第99个百分点的初步估计分别为9.20、8.00和8.60 ng / L。根据AccuTnI峰值浓度,在108例心肌损伤患者中,应用hs-cTnI测定法在2个最早的标本上应用变化标准确定的患者为81%(95%CI 73%–88%),而62%(53%)结论:–71%)使用AccuTnI测定法(P <0.001)。结论:尽管需要进行更广泛的验证研究,但这种Beckman Coulter hs-cTnI测定法似乎可以更早地检测出发展中的心肌损伤患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号